

13 April 2018

ASX Announcement

Lifespote Health Ltd unique cannabis vaporizer ahead of schedule, commercialization plans accelerated

- **Completion of the “reference standard” ahead of schedule**
- **Integration into the medically certified BodyTel software infrastructure**
- **Discussions on cooperation with international cannabis companies**
- **Aiming for sales cooperation and further funding end of Q3/2018**

Lifespote Health Ltd (Company) is pleased to announce that its subsidiary Seng Vital Pty Ltd, in which Lifespote Health holds a 50 percent interest, has entered the final phase of its most important project in medical cannabis applications with the development of the “reference standard” sample of the vaporizer for medical cannabis delivery. This phase of the project is expected to be completed by the end of July, well ahead of schedule and will be followed by commercialization.

The vaporizer allows cannabis to be taken in the form of vapors extracted from oils or herbs. What makes the vaporizer unique is its embedment in the medically certified software infrastructure of BodyTel GmbH, a wholly owned subsidiary of Lifespote Health Ltd. The BodyTel infrastructure allows both patients and authorized physicians to retrieve and evaluate the readings and data collected by the vaporizer, controlling the application history “from the outside” (BodyTel Data Monitoring & Collection).





In addition, the vaporizer will be equipped with unique security features developed by Seng Vital. Central elements of the concept are the integration of a fingerprint sensor and the authorization of the active ingredient capsules based on the processing of the central pharmaceutical number (PZN, nationwide central key for pharmaceuticals). Through these ingredients, the vaporizer has the potential to be recognized as a medical device by the US Food and Drug Administration.

Discussions regarding a long-term supply contract are advancing and talks are also underway on a partnership to offer customized capsules for simple and safe dosing of the active substance.

Collaboration with well-known international cannabis companies to secure further funding until the end of Q3/2018 as well as sales cooperation are advancing well and the Company expects to remain ahead of schedule in both development and commercial milestones.

With the all-in-one vaporizer integrated into the BodyTel system, Lifespot Health is addressing a huge growth market. According to a study by Arcview Market Research and BSD Analytics, the global market for legal cannabis applications will grow to over US\$ 57 billion in annual revenue by 2027. Of these, more than US\$ 19 billion will be spent on medical cannabis applications.

"We think we're creating a gold standard for vaporizers with our all-in-one vaporizer. No other device combines safety and ease of use at such a high level. Due to the exact dosage and complete monitoring by means of our certified BodyTel platform, that has already been tested by several well-known medical device manufacturers, we will bring a product to the market which meets all requirements for a medical device", says Heiner Emden, Executive Director of Lifespot Health Ltd. & Managing Director of BodyTel GmbH.

For more information, please visit the website at www.lifespot-health.com.

About Lifespot Health Ltd. *Lifespot Health operates within the digital health sector and is focused on developing and commercializing medical diagnostic and monitoring technology. Our systems and applications aim to bring efficiencies in the medical system to clients and end users, saving time and money. Lifespot Health integrates software to combine enhanced sensor technology with self-learning algorithms, allowing patients to monitor chronic diseases and critical conditions with their smartphones.*

Justyn Stedwell
Company Secretary
On behalf of the Board of Directors
Lifespot Health Ltd